Lymph Node Structure and Function in Tolerance: Role of Laminins

耐受性中的淋巴结结构和功能:层粘连蛋白的作用

基本信息

  • 批准号:
    10046835
  • 负责人:
  • 金额:
    $ 46.35万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2015
  • 资助国家:
    美国
  • 起止时间:
    2015-04-20 至 2025-05-31
  • 项目状态:
    未结题

项目摘要

Project Summary/Abstract Foxp3+ regulatory T cells (Treg) are required for transplant tolerance, however, where and when they are induced and activated remains uncertain. During costimulatory blockade induced tolerization, naïve T cells migrate to the lymph node (LN), but not the spleen, where they are stimulated by alloantigen presenting plasmacytoid dendritic cells (pDC), and differentiate into induced Treg (iTreg). We have identified the adhesion and chemokine molecules which orchestrate tolerance by directing the localized accumulation of Treg in the cortical ridge (CR) of the LN where the high endothelial venules (HEV) are present. HEV are the main gatekeeper of T cell trafficking. Overall, naive T cells migrate to the CR and become iTreg, while T cells that become anergic or apoptotic migrate to other regions of the LN. Thus, a unique LN domain is required for the generation and activity of tolerogenic iTreg. The overall hypothesis is that this domain is required for tolerance, and the goal is to define the key events that regulate this structure and can be leveraged for tolerization. In this specialized LN domain the stromal fiber laminin α4:α5 ratios determine the response to alloantigen. Laminins surrounding the HEV and CR act as gatekeepers for T cell fate by directly instructing T cell entry, conversion to iTreg, and the fate of later T cell cohorts, with a high laminin α4:α5 ratio favoring tolerance. Laminin α4 (termed 411 for αβγ chains) promotes CD4 and CD8 T cell motility and transendothelial and interstitial migration into the HEV and CR, promotes Foxp3 expression and iTreg maturation, and inhibits effector T cell differentiation. In contrast, laminin α5 (or 511) inhibits migration into HEV, yet costimulates T cell proliferation and inflammatory Th17. T cells recognize laminin α5 using both integrin α6 and α-dystroglycan (αDG) receptors, and αDG-laminin α5 specifically induces Th17. Antibodies to these receptors prolong graft survival and enhance iTreg migration to the CR. We generalized these concepts in other models (colitis, tumor immunity, chronic rejection, vaccination), and in each case immunity correlated with decreased laminin α4:α5 ratios, while tolerance required an increased ratio. Altogether, our new data indicate that stromal cells regulate the LN laminin α4:α5 ratio and control the fate of the immune response to inflammation and immunity (low ratio) or to suppression and tolerance (high ratio). Our specific hypothesis is that LN stromal cells integrate immune cues and thus regulate laminin structures, and this integration is a final common pathway that channels the immune response and allograft outcomes. Thus, remodeling of laminins is a facet of innate immunity whereby immune cues stimulate stromal cells (FRC, LEC, BEC) to modify LN structure, which subsequently determines adaptive immunity. The corollaries are: 1) laminins regulate the response to inflammation and immunity, which results in pro- inflammatory LN structures or even the pathologic response of immunologic scarring; and 2) laminins regulate the response to suppression and tolerance and result in homeostatic and pro-tolerogenic LN structures.
项目总结/文摘

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Jonathan S Bromberg其他文献

Islet implantation in a pocket
胰岛植入在囊中
  • DOI:
    10.1038/nbt.3216
  • 发表时间:
    2015-05-12
  • 期刊:
  • 影响因子:
    41.700
  • 作者:
    Jonathan S Bromberg
  • 通讯作者:
    Jonathan S Bromberg

Jonathan S Bromberg的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Jonathan S Bromberg', 18)}}的其他基金

Mechanisms of microbiome-driven cardiac allograft outcomes
微生物组驱动的同种异体心脏移植结果的机制
  • 批准号:
    10477625
  • 财政年份:
    2022
  • 资助金额:
    $ 46.35万
  • 项目类别:
Mechanisms of microbiome-driven cardiac allograft outcomes
微生物组驱动的同种异体心脏移植结果的机制
  • 批准号:
    10621899
  • 财政年份:
    2022
  • 资助金额:
    $ 46.35万
  • 项目类别:
Reshaping lymph node stroma for transplant tolerance
重塑淋巴结基质以提高移植耐受性
  • 批准号:
    10662321
  • 财政年份:
    2020
  • 资助金额:
    $ 46.35万
  • 项目类别:
Reshaping lymph node stroma for transplant tolerance
重塑淋巴结基质以提高移植耐受性
  • 批准号:
    10224026
  • 财政年份:
    2020
  • 资助金额:
    $ 46.35万
  • 项目类别:
Reshaping lymph node stroma for transplant tolerance
重塑淋巴结基质以提高移植耐受性
  • 批准号:
    10024598
  • 财政年份:
    2020
  • 资助金额:
    $ 46.35万
  • 项目类别:
Reshaping lymph node stroma for transplant tolerance
重塑淋巴结基质以提高移植耐受性
  • 批准号:
    10431927
  • 财政年份:
    2020
  • 资助金额:
    $ 46.35万
  • 项目类别:
Immunological and functional consequences triggered by the gut microbiota regulate alloimmunity and cardiac transplant outcome
肠道微生物群引发的免疫和功能后果调节同种免疫和心脏移植结果
  • 批准号:
    10439697
  • 财政年份:
    2019
  • 资助金额:
    $ 46.35万
  • 项目类别:
Immunological and functional consequences triggered by the gut microbiota regulate alloimmunity and cardiac transplant outcome
肠道微生物群引发的免疫和功能后果调节同种免疫和心脏移植结果
  • 批准号:
    10202721
  • 财政年份:
    2019
  • 资助金额:
    $ 46.35万
  • 项目类别:
Immunological and functional consequences triggered by the gut microbiota regulate alloimmunity and cardiac transplant outcome
肠道微生物群引发的免疫和功能后果调节同种免疫和心脏移植结果
  • 批准号:
    9975884
  • 财政年份:
    2019
  • 资助金额:
    $ 46.35万
  • 项目类别:
Immunological and functional consequences triggered by the gut microbiota regulate alloimmunity and cardiac transplant outcome
肠道微生物群引发的免疫和功能后果调节同种免疫和心脏移植结果
  • 批准号:
    9795098
  • 财政年份:
    2019
  • 资助金额:
    $ 46.35万
  • 项目类别:

相似海外基金

Operational tolerance induction by alloantigen-induced Treg cell therapy in rat lung transplantation
同种异体抗原诱导的 Treg 细胞疗法在大鼠肺移植中诱导操作耐受
  • 批准号:
    23K08289
  • 财政年份:
    2023
  • 资助金额:
    $ 46.35万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Selective induction of alloantigen-specific humoral tolerance by MHC-Fc fusion proteins
MHC-Fc 融合蛋白选择性诱导同种异体抗原特异性体液耐受
  • 批准号:
    10432434
  • 财政年份:
    2022
  • 资助金额:
    $ 46.35万
  • 项目类别:
Requirements and mechanisms of alloantigen-induced cardiac allograft survival by cDC1s
cDC1同种异体抗原诱导心脏同种异体移植物存活的要求和机制
  • 批准号:
    10744193
  • 财政年份:
    2022
  • 资助金额:
    $ 46.35万
  • 项目类别:
Requirements and mechanisms of alloantigen-induced cardiac allograft survival by cDC1s
cDC1同种异体抗原诱导心脏同种异体移植物存活的要求和机制
  • 批准号:
    10534556
  • 财政年份:
    2022
  • 资助金额:
    $ 46.35万
  • 项目类别:
Selective induction of alloantigen-specific humoral tolerance by MHC-Fc fusion proteins
MHC-Fc 融合蛋白选择性诱导同种异体抗原特异性体液耐受
  • 批准号:
    10612453
  • 财政年份:
    2022
  • 资助金额:
    $ 46.35万
  • 项目类别:
Preventing GVHD by inhibition of alloantigen presentation in the gut
通过抑制肠道内同种抗原的呈现来预防 GVHD
  • 批准号:
    10204102
  • 财政年份:
    2019
  • 资助金额:
    $ 46.35万
  • 项目类别:
Preventing GVHD by inhibition of alloantigen presentation in the gut
通过抑制肠道内同种抗原的呈现来预防 GVHD
  • 批准号:
    10443701
  • 财政年份:
    2019
  • 资助金额:
    $ 46.35万
  • 项目类别:
Preventing GVHD by inhibition of alloantigen presentation in the gut
通过抑制肠道内同种抗原的呈现来预防 GVHD
  • 批准号:
    10737340
  • 财政年份:
    2019
  • 资助金额:
    $ 46.35万
  • 项目类别:
Preventing GVHD by inhibition of alloantigen presentation in the gut
通过抑制肠道内同种抗原的呈现来预防 GVHD
  • 批准号:
    10652374
  • 财政年份:
    2019
  • 资助金额:
    $ 46.35万
  • 项目类别:
Generation of alloantigen-specific Designer Platelets for diagnostic and investigative use
生成用于诊断和研究用途的同种异体抗原特异性设计血小板
  • 批准号:
    9005358
  • 财政年份:
    2016
  • 资助金额:
    $ 46.35万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了